nAbCyte™ CDx: One-time treatment. Zero room for error.
Break through in partnership
An estimated 6,000 people in the United States live with hemophilia B. nAbCyte™—the first CDx for a cell-based gene therapy—offers new hope in delivering the right treatment to the right patients.
Explore our gene therapy and companion diagnostic services
Press release
FDA approved the first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with hemophilia B.
nAbCyte testing program
The nAbCyte Hemophilia B Testing Program helps determine patient eligibility for treatment with Pfizer’s hemophilia B gene therapy.
Cell and gene therapy
From research and development of cell and gene therapy products to next-generation sequencing testing, you need answers—our scientists are here to help.
Companion diagnostics
Parallel development of a companion diagnostic with a novel therapeutic is challenging—but the value of proving your treatment’s efficacy with targeted biomarkers has never been greater.